A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
CB-03-01 is being developed for the topical treatment of acne vulgaris, an androgen-dependent
 skin disorder. The purpose of this study is to compare the safety and efficacy of multiple
 concentrations of CB-03-01 to vehicle in the treatment of acne vulgaris.
Inclusion Criteria:

 -  Subject is male or non-pregnant female. Females must be post-menopausal, surgically
 sterile or using highly effective birth control methods.

 -  Subject has provided written and verbal informed consent/assent.

 -  Subject has facial acne vulgaris (including the nose).

 -  Subject is willing to comply with study instructions and return to the clinic for
 required visits.

 -  Subject has used the same type and brand of make-up, other facial products (including
 cleanser) and hair products (e.g., shampoo, gel, hair spray, mousse, etc.) for at
 least one month prior to the study start and agrees to continue his/her other general
 skin and hair care products and regimen for the entire study.

 Exclusion Criteria:

 -  Subject is pregnant, lactating, or is planning to become pregnant during the study.

 -  Subject is currently enrolled in an investigational drug or device study.

 -  Subject has received an investigational drug or been treated with an investigational
 device within 30 days prior to the study start.

 -  Subject has the need or plans to be exposed to artificial tanning devices or excessive
 sunlight during the trial

 -  Subject has used any of the following topical anti-acne preparations or procedures on
 the face:

 -  Topical anti-acne treatments including but not limited to over-the-counter acne
 cleaners or treatments, benzoyl peroxide, antibiotics, azelaic acid, sulfa based
 products, corticosteroids and salicylic acid within two weeks of the initiation
 of treatment.

 -  Retinoids, including tazarotene, adapalene, tretinoin, within four weeks of the
 initiation of treatment.

 -  Light treatments, microdermabrasion or chemical peels within eight weeks of the
 initiation of treatment.

 -  Subject has used the following systemic anti-acne medications:

 -  Corticosteroids (including intramuscular and intralesional injections) within
 four weeks of the initiation of treatment. Inhaled, intranasal or ocular
 corticosteroids are allowed if use is stable (stable use is defined as dose and
 frequency unchanged for at least four weeks prior to the initiation of
 treatment).

 -  Antibiotics within four weeks of the initiation of treatment with the exception
 of five days or less of antibiotic therapy during this period, but with no
 antibiotics use permitted within one week prior to the initiation of treatment.

 -  Spironolactone within eight weeks of the initiation of treatment with the
 exception of five days or less of spironolactone therapy during this period, but
 with no spironolactone use permitted within one week prior to the initiation of
 treatment.

 -  Retinoid therapy within six months of the initiation of treatment.